Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK)

M. Ghielmini, K. Rufibach, G. Salles, L. Leoncini-Franscini, C. Léger-Falandry, S. Cogliatti, M. Fey, G. Martinelli, R. Stahel, A. Lohri, N. Ketterer, M. Wernli, T. Cerny, S. F Hsu Schmitz

Research output: Contribution to journalArticle

Abstract

Background: Predictive factors of rituximab efficacy and its effect on the immune system are still not defined. Patients and methods: Three hundred and six patients with follicular or mantle cell lymphoma received four weekly doses of rituximab (induction) and no further treatment (arm A) or four more doses at 2-month intervals (arm B). Results: Response rate to induction was 44%. Independent predictive factors for response were disease bulk

Original languageEnglish
Pages (from-to)1675-1682
Number of pages8
JournalAnnals of Oncology
Volume16
Issue number10
DOIs
Publication statusPublished - Oct 2005

Keywords

  • Fc-γ receptor
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Predictive factors
  • Rituximab
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK)'. Together they form a unique fingerprint.

  • Cite this

    Ghielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Léger-Falandry, C., Cogliatti, S., Fey, M., Martinelli, G., Stahel, R., Lohri, A., Ketterer, N., Wernli, M., Cerny, T., & Schmitz, S. F. H. (2005). Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology, 16(10), 1675-1682. https://doi.org/10.1093/annonc/mdi320